Showing results (2211-2220 of 3,237) with videos related to

Sort By:
Pageof 324
Antiviral Therapy|May 29, 2009
Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in BeninDjimon Marcel Zannou, Lise Denoeud, Karine Lacombe, et al.
The Lancet. Rheumatology|September 7, 2025
Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for preventionValentine Ribier, Jérôme Hadjadj, Vincent Jachiet, et al.
JMIR Rehabilitation and Assistive Technologies|June 15, 2026
Health Care Providers' Perspectives on a Hybrid Outpatient Stroke Telerehabilitation Program: Qualitative Implementation StudyMarina B Wasilewski, Shaghayegh Mirbaha, Karl Wong, et al.
Gene|October 18, 2002
Characterization of the nm23-M2, nm23-M3 and nm23-M4 mouse genes: comparison with their human orthologsK Massé, S Dabernat, P-M Bourbon, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 18, 2022
Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait ParametersValérie Cochen De Cock, Dobromir Dotov, Sandy Lacombe, et al.
Cell Research|March 30, 2011
Calcium-dependent modulation and plasma membrane targeting of the AKT2 potassium channel by the CBL4/CIPK6 calcium sensor/protein kinase complexKatrin Held, François Pascaud, Christian Eckert, et al.
International Journal of Radiation Biology|July 29, 2008
Mammalian cells loaded with platinum-containing molecules are sensitized to fast atomic ionsN Usami, Y Furusawa, K Kobayashi, et al.
Blood|September 10, 2010
Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesisHana Forejtnikovà, Maud Vieillevoye, Yael Zermati, et al.
European Journal of Haematology|February 19, 2000
Increased liposome-mediated gene transfer into haematopoietic cells grown in adhesion to stromal or fibroblast cell line monolayersG Marit, Y Cao, P Froussard, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2003
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development groupE Briasoulis, N Pavlidis, C Terret, et al.
Pageof 324